AIDS Research and Human Retroviruses 10/2014; 30 Suppl 1:A278. DOI:10.1089/aid.2014.5627.abstract · 2.46 Impact Factor
AIDS Research and Human Retroviruses 10/2014; 30 Suppl 1:A101. DOI:10.1089/aid.2014.5188.abstract · 2.46 Impact Factor
AIDS Research and Human Retroviruses 10/2014; 30 Suppl 1:A223. DOI:10.1089/aid.2014.5487.abstract · 2.46 Impact Factor
Sexually Transmitted Infections 07/2013; 89(Suppl 1):A262-A262. DOI:10.1136/sextrans-2013-051184.0814 · 3.08 Impact Factor
Screening for HPV-driven cervical dysplasia and neoplasia is a significant public health concern in the developing world. The purpose of this study was to use a manual, low-cost liquid-based Pap preparation to determine HPV prevalence in HIV-positive and HIV-negative young women in Kampala, Uganda and to correlate cervical cytopathology with HPV-DNA genotype. About 196 post-partum women aged 18-30 years underwent rapid HIV testing and pelvic examination. Liquid-based cervical cytology samples were processed using a low-cost manual technique. A DNA collection device was used to collect specimens for HPV genotyping. HIV and HPV prevalence was 18 and 64%, respectively. Overall, 49% of women were infected with a high-risk HPV genotype. The most common high-risk HPV genotypes were 16 (8.2%), 33 (7.7%), 35 (6.6%), 45 (5.1%), and 58 (5.1%). The prevalence of HPV 18 was 3.6%. HIV-positive women had an HPV prevalence of 86% compared to 59% in HIV-negative women (P = 0.003). The prevalence of HPV 16/18 did not differ by HIV status. HIV-positive women were infected with a significantly greater number of HPV genotypes compared to HIV-negative women. By multivariate analysis, the main risk factor for HPV infection was coinfection with HIV. HIV-positive women were four times more likely to have abnormal cytology than HIV-negative women (43% vs. 11.6%, P < 0.001). These data highlight that HIV infection is a strong risk factor for HPV infection and resultant abnormal cervical cytology. Notably, the manual low-cost liquid-based Pap preparation is practical in this setting and offers an alternate method for local studies of HPV vaccine efficacy.
Diagnostic Cytopathology 01/2009; 38(8):555-63. DOI:10.1002/dc.21249 · 1.52 Impact Factor